Hydroquinone for skin lightening: Safety profile, duration of use and when should we stop?

References

• Burke PA, Maibach HI. Exogenous ochronosis: An overview. J Dermatol Treat. 1997;8:21–26.
   Web of Science ®Google Scholar
• Hydroquinone Task Group, Nonprescription Drug Manufacturers Association. Salient observations from the published literature on exogenous ochronosis reportedly associated with skin discoloration fade products. Washington, DC: Nonprescription Drug Manufacturers Association; 12 May 1992.
   Google Scholar
• Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther. 2007;20:308–313.
   PubMed Web of Science ®Google Scholar
• Nordlund JJ, Grimes PE, Ortonne JP. The safety of hydroquinone. J Eur Acad Dermatol Venereol. 2006;20:781–787.
   PubMed Web of Science ®Google Scholar
• Levitt J. The safety of hydroquinone: A dermatologist's response to the 2006 Federal Register. J Am Acad Dermatol. 2007;57:854–872.
   PubMed Web of Science ®Google Scholar
• Toombs EL. Hydroquinone – What is its future? Dermatol Ther. 2007;20:149–156.
   PubMedGoogle Scholar
• Westerho W, Kooyers TJ. Hydroquinone and its analogues in dermatology – A potential risk. J Cosmet Dermatol. 2005;4:55–59.
   PubMedGoogle Scholar
• Nordlund J, Grimes P, Ortonne J-P. Letters to the editor: The safety of hydroquinone. J Cosmet Dermatol. 2006;5:168–170.
   PubMedGoogle Scholar
• Palm MD, Toombs EL. Hydroquinone and the FDA – The debate? J Drugs Dermatol. 2007;6:122.
   PubMedGoogle Scholar
• O'Donoghue JL. Twenty-fourth Commission Directive 2000/6/EC. Official J Eur Commun. 2000;L56:42–46
   Google Scholar
• Halder RM, Richards GM. Management of dischromias in ethnic skin. Dermatologic Therapy. 2004;17:151–157.
   PubMedGoogle Scholar
• Goldsmith LA. Cutaneous changes in errors of amino acid metabolism: Alkaptonuria. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF, editors. Dermatology in general medicine. Chap 148. New York: McGraw Hill; 1993. p. 1841–1845.
   Google Scholar
• Offel JV, DeClerck L, Francx L, Stevens WJ. The clinical manifestations of ochronosis: A review. Acta Clin Belg. 1995;50:358–362.
   PubMedGoogle Scholar
• Dogliotti M, Leibowitz M. Granulomatous ochronosis: A cosmetic-induced skin disorder in blacks. S Afr Med J. 1979;56:757–760.
   PubMed Web of Science ®Google Scholar
• Cheryl YL, Maibach H. Exogenous ochronosis: An update on clinical features, causative agents and treatment options. Am J Clin Dermatol. 2001;2:213–217.
   PubMedGoogle Scholar
• Findlay GH, LMorrison JG, Simson IW. Exogenous ochronosis and pigmented colloid millium from hydroquinone bleaching creams. J Dermatol. 1975;93:613–622.
   Google Scholar
• Siak KT, Chee SS, Chee LG. Hydroquinone-induced exogenous ochronosis in Chinese – Two case reports and a review. Int J Dermatol. 2008;47:639–640.
   PubMedGoogle Scholar
• Charlín R, Barcaui CB, Kac BK, Soares DB, Rabello-Fonseca R, Azulay-Abulafia L. Hydroquinone-induced exogenous ochronosis: A report of four cases and usefulness of dermoscopy. Int J Dermatol. 2008;47:19–23.
   PubMedGoogle Scholar
• Diven DG, Smith EB, Pupo RA, Mike Lee. Hydroquinone-induced localized exogenous ochronosis treated with dermabrasion and CO2 laser. J Dermatol Surg Oncol. 1990;16:1018–1022.
   PubMedGoogle Scholar
• Olumide YM, Akinkugbe AO, Altraide D, Mohammed T, Ahamefule N, Ayanlono S, Complications of chronic use of skin lightening cosmetics. Int J Dermatol. 2008;47:344–53.
   PubMed Web of Science ®Google Scholar
• Ruocco V, Florio M. Fish-odor syndrome: An olfactory diagnosis. Int J Dermatol. 1995;34:92–93.
   PubMedGoogle Scholar
• Touart D, Sau P. Cutaneous deposition diseases. Part II. J Am Acad Dermatol. 1998;39:527–544.
   PubMedGoogle Scholar
• Hoshaw RA, Zimmerman KG, Menter A. Ochronosis-like pigmentation from hydroquinone bleaching creams in American blacks. Arch Dermatol. 1985;121:105–108.
   PubMedGoogle Scholar
• DeCaprio AP. The toxicology of hydroquinone – Relevance to occupational and environmental exposure. Crit Rev Toxicol. 1999;29:283–330.
   PubMed Web of Science ®Google Scholar
• O'Donoghue JL. Hydroquinone and its analogues in dermatology – A risk–benefit viewpoint. J Cosmet Dermatol. 2006;5:196–203.
   PubMedGoogle Scholar
• National Toxicology Program. Toxicology and carcinogenesis studies of hydroquinone in F-344/N rats and B6C3F1 mice. Research Triangle Park, NC: National Institutes of Health; 1989. Publication No. 90-2821.
   Google Scholar
• International Agency for Research on Cancer. Hydroquinone. In: IARC monographs on the evaluation of carcinogenic risks to humans: Re-evaluation of some organic chemicals. Hydrazine and hydrogen peroxide. Vol. 71, Part 2. Geneva: World Health Organization; 1999. p. 691–719.
   Google Scholar
• Pifer JW, Herane FT, Swanson FA, John L. O'Donoghue. Mortality study of employees engaged in the manufacture and use of hydroquinone. Int Arch Occup Environ Health. 1995;67:267–280.
   PubMed Web of Science ®Google Scholar
• Bellew SG, Alster TS. Treatment of exogenous ochronosis with a Q-switched alexandrite (755 nm) laser. Dermatol Surg. 2004;30:555–558.
   PubMed Web of Science ®Google Scholar
• Lacz NL, Vafaie J, Kihiczak NI. Postinflammatory hyperpigmentation: A common but troubling condition. Int J Dermatol. 2004;43:362–365.
   PubMed Web of Science ®Google Scholar
• Pandya AG, Guevara IL. Disorders of hyperpigmentation. Dermatol Clin. 2000;18:91–98.
   PubMed Web of Science ®Google Scholar